Evidence map›Paper›PMID 38075671›Full record

ArticleChemical science2023

Maruthi Kumar Narayanam, Jonathan E Tsang, Shili Xu, David A Nathanson, Jennifer M Murphy

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Maruthi Kumar NarayanamDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA.
Jonathan E TsangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA.
Shili XuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA.
David A NathansonDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA.
Jennifer M MurphyDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA.ORCID https://orcid.org/0000-0002-8492-4918
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Small animal combined PET/CT systemS10OD026917 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHATZIIOANNOU, ARION XENOFON · 2020 to 2020
$750k
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NIH HHS S10 OD026917
6 · The paper itself

Abstract

Significant evidence suggests that the failure of clinically tested epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (

Identifiers

PMID38075671
PMCPMC10699577
OpenAlexW4388543837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.